Results for tasimelteon translation from English to Croatian

tasimelteon 20 mg
tazimelteon 20 mg

tasimelteon is extensively metabolised.
tazimelteon se ekstenzivno metabolizira.

the active substance is tasimelteon.
djelatna tvar je tazimelteon.

hetlioz 20 mg hard capsules tasimelteon
hetlioz 20 mg tvrde kapsule tazimelteon

potential effect of alcohol on tasimelteon
mogući utjecaj alkohola na tazimelteon

each hard capsule contains 20 mg tasimelteon.
svaka tvrda kapsula sadrži 20 mg tazimelteona.

each hard capsule contains 20 mg of tasimelteon.
svaka tvrda kapsula sadrži 20 mg tazimelteona.

race does not affect apparent clearance of tasimelteon.
rasa ne utječe na prividni klirens tazimelteona.

cyp2c19) in the metabolism of tasimelteon is unknown.
cyp2c19) u metabolizmu tazimelteona nije poznata.

potential for other medicinal products to affect tasimelteon
mogućnost utjecaja drugih lijekova na tazimelteon

tasimelteon functions as a dmra at the mt1 and mt2 receptors.
tazimelteon djeluje kao dmra na receptorima mt1 i mt2.

there are no data on the effects of tasimelteon on human fertility.
ne postoje podaci o učincima tazimelteona na plodnost u ljudi.

it is unknown whether tasimelteon/metabolites are excreted in human milk.
nije poznato izlučuje li se tazimelteon/metaboliti u majčino mlijeko u ljudi.

tasimelteon exhibits a greater affinity for the mt2 as compared to the mt1 receptor.
tazimelteon pokazuje veći afinitet za receptore mt2 u odnosu na receptore mt1.

cyp1a2 and cyp3a4 are enzymes identified to play a role in the metabolism of tasimelteon.
cyp1a2 i cyp3a4 su enzimi za koje je utvrđeno da imaju ulogu u metabolizmu tazimelteona.

as a precautionary measure, it is preferable to avoid the use of tasimelteon during pregnancy.
kao mjera opreza, preporučuje se izbjegavanje uporabe tazimelteona tijekom trudnoće.

major metabolites had 13-fold or less activity at melatonin receptors compared to tasimelteon.
glavni metaboliti imali su najmanje 13 puta manju aktivnost na receptorima melatonina u usporedbi s tazimelteonom.

medicinal products that inhibit cyp1a2 and cyp3a4 have been shown to alter the metabolism of tasimelteon in vivo.
pokazalo se da lijekovi koji inhibiraju cyp1a2 i cyp3a4 mijenjaju metabolizam tazimelteona in vivo.

in pregnant rats administered tasimelteon during the period of organogenesis, there were no effects on embryofoetal development.
u gravidnih štakora koji su tijekom organogeneze primali tazimelteon nije bilo utjecaja na embriofetalni razvoj.

adverse reactions leading to discontinuation occurred in 2.3% of tasimelteon-treated patients.
nuspojave koje su rezultirale prekidom uporabe lijeka zabilježene su kod 2,3 % bolesnika liječenih tazimelteonom.